Myriad Genetics (MYGN) CEO buys 40,000 shares in open market

Rhea-AI Filing Summary

Myriad Genetics President and CEO Samraat S. Raha reported an open-market purchase of 40,000 shares of common stock. The shares were bought at a weighted average price of $4.9961 per share in multiple trades between $4.97 and $5.00. Following this transaction, Raha directly owns 493,104 shares of Myriad Genetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raha Samraat S.

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		P		40,000	A	$4.9961(1)	493,104	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.97 to $5.00, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	By: Justin Hunter For: Samraat S. Raha	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MYGN President and CEO report?

Myriad Genetics President and CEO Samraat S. Raha reported buying 40,000 shares of common stock in an open-market transaction. The weighted average purchase price was $4.9961 per share, with individual trades executed between $4.97 and $5.00, increasing his direct holdings to 493,104 shares.

How many Myriad Genetics (MYGN) shares does the CEO now own?

After the reported transaction, CEO Samraat S. Raha directly owns 493,104 Myriad Genetics common shares. This reflects the addition of 40,000 shares purchased in the open market at a weighted average price of $4.9961 per share, executed across multiple trades within a narrow price range.

At what prices were the MYGN shares purchased by the CEO?

The CEO’s 40,000-share purchase was executed at prices ranging from $4.97 to $5.00 per share. The filing reports a weighted average purchase price of $4.9961 per share, reflecting multiple individual trades within that narrow band during the open-market transaction.

Was the MYGN CEO’s transaction an open-market purchase or another type?

The transaction was an open-market purchase of Myriad Genetics common stock by CEO Samraat S. Raha. It is coded as a purchase transaction, with 40,000 shares acquired at a weighted average price of $4.9961 per share, according to the Form 4 disclosure data provided.

What does the Form 4 footnote reveal about MYGN trade pricing?

The footnote explains that the reported $4.9961 price is a weighted average. The 40,000 shares were bought in multiple trades between $4.97 and $5.00 per share, and detailed pricing by trade is available from Myriad Genetics, any security holder, or the SEC staff upon request.